The eGFR cut-off for starting an SGLT2 inhibitor has dropped repeatedly over the past several years as trial data showed these drugs protect kidneys and hearts at levels of kidney function that were once considered too low. Early prescribing labels typically required an eGFR of 45 or even 60, but major guidelines now permit initiation down to 20, and once you’re already on the drug, evidence supports continuing it all the way to dialysis or transplant. That shifting threshold reflects one of the more dramatic changes in kidney-disease management in recent memory, and understanding why it moved matters for anyone prescribed these medications or managing chronic kidney disease.
How SGLT2 Inhibitors Affect the Kidney
SGLT2 inhibitors block the reabsorption of sodium and glucose in the first stretch of the kidney’s filtering tubes, the proximal tubule. Normally, most of the glucose your kidneys filter gets pulled right back into the bloodstream at that site. When the drug blocks that process, glucose spills into the urine, and extra sodium comes along with it. That extra sodium delivery downstream triggers a built-in safety mechanism called tubuloglomerular feedback, which tells the kidney to ease off on how hard it’s filtering blood through each individual filtering unit.1PubMed Central. Intrarenal Mechanisms of Sodium-Glucose Cotransporter-2 Inhibitors on Tubuloglomerular Feedback and Natriuresis The result is a reduction in glomerular hyperfiltration, the state where each kidney filter is working too hard and slowly burning itself out.
Beyond that core mechanism, SGLT2 inhibitors also inhibit sodium-proton exchange, increase sodium delivery to the loop of Henle, and have broader effects on blood pressure and fluid balance.2PubMed. Antihypertensive and Renal Mechanisms of SGLT2 (Sodium-Glucose Linked Transporter 2) Inhibitors They also appear to suppress inflammation and fibrosis in the kidney, which is part of why their benefits extend well beyond blood-sugar control.3American Journal of Physiology-Endocrinology and Metabolism. SGLT2 inhibitors use in kidney disease: what did we learn? This constellation of effects is why the drugs help people with and without diabetes, and why the eGFR threshold matters in a different way than it does for purely glucose-lowering medications.
The Initial eGFR Dip and Why It Matters
Almost everyone who starts an SGLT2 inhibitor sees their eGFR drop by roughly 4 to 6 points in the first weeks.4Clinical Kidney Journal. Kidney hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in diabetes: physiology and clinical implications If your eGFR was 35 and it falls to 30 after starting the drug, that can look alarming on a lab report. But this dip is a direct and expected consequence of the drug reducing hyperfiltration. Think of it less as kidney damage and more as the kidney being told to stop overworking. The drop is reversible: if you stop the drug, eGFR bounces back.
In one analysis of the CREDENCE trial, patients with an eGFR between 30 and 45 who started canagliflozin saw an initial drop of about 2 points, and then their kidney function declined far more slowly than the placebo group over the following years. The between-group difference in the rate of eGFR decline was about 2.6 points per year in favor of canagliflozin.5PubMed Central. Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial In other words, you trade a small, reversible dip upfront for substantially slower kidney deterioration over years. Current guidelines say this initial dip alone should not lead to stopping the drug. KDIGO recommends investigating further only if eGFR drops more than 30% after starting, and even then, withdrawal isn’t necessarily the answer.6Kidney Medicine. SGLT2 Inhibitors and the eGFR Cut-Off: What It Means
This dip creates a real psychological barrier, though. A doctor watching a patient’s already-low kidney function fall further after prescribing a new drug faces pressure to stop it. That instinct is understandable but, in most cases, counterproductive. The evidence consistently shows that the patients who tolerate the initial dip and stay on the drug do better over time than those who stop.
Trial Evidence That Pushed the Threshold Lower
Three large trials reshaped how nephrologists think about eGFR thresholds for SGLT2 inhibitors, each one enrolling patients with worse kidney function than the trial before it.
The CREDENCE trial tested canagliflozin in people with type 2 diabetes and kidney disease. It enrolled patients with eGFR as low as 30 and found consistent kidney and cardiovascular benefits across the entire range, including those with eGFR below 30 who were studied in a subgroup analysis. The hazard ratio for kidney failure was similar whether patients started above or below 30, and no meaningful safety differences emerged between the groups.7PubMed Central. Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2: Subgroup Analysis of the Randomized CREDENCE Trial The subgroups with lower eGFRs, who were at higher absolute risk, actually got larger absolute benefits for kidney outcomes.5PubMed Central. Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial
DAPA-CKD tested dapagliflozin in a broader chronic kidney disease population that included people without diabetes. Over about two and a half years, dapagliflozin cut the risk of the main kidney endpoint by 39% and reduced the risk of the kidney-specific composite by 44%. All-cause death was 31% lower. The benefits held regardless of whether patients had diabetes.8PubMed. Dapagliflozin in Patients with Chronic Kidney Disease This was a watershed moment because it showed the kidney protection wasn’t just an indirect benefit of better blood sugar.
EMPA-KIDNEY went furthest, enrolling patients with eGFR as low as 20. The trial included people with a wider variety of kidney disease causes and tested empagliflozin. It was stopped early because the drug was clearly working: kidney disease progression or cardiovascular death dropped by 28%, and results were consistent across eGFR ranges and regardless of diabetes status.9PubMed. Empagliflozin in Patients with Chronic Kidney Disease The enrolled patients had lower eGFR at baseline than in any prior kidney trial of SGLT2 inhibitors.10PubMed Central. SGLT2 Inhibitors and the eGFR Cut-Off: What It Means The drug also reduced all-cause hospitalization by 14%, with broadly consistent effects even in patients who were frail or taking many medications.11PubMed Central. Frailty, Multimorbidity, and Polypharmacy: Exploratory Analyses of the Effects of Empagliflozin from the EMPA-KIDNEY Trial
How the Guidelines Have Shifted
The guideline landscape reflects this accumulating evidence, though it has moved in fits and starts depending on when each organization last updated its recommendations. The 2019 European Society of Cardiology guidelines recommended SGLT2 inhibitors for people with type 2 diabetes and eGFR between 30 and 90. The 2020 KDIGO guideline set the initiation threshold at eGFR 30 and noted it was reasonable to continue below that. By 2022, the American Diabetes Association had moved its threshold to eGFR 25 or above.12Nephrology Dialysis Transplantation. Clinical implications and guidelines for CKD in type 2 diabetes
Post-EMPA-KIDNEY, the practical consensus has converged further. Most updated guidance now supports initiation at eGFR 20 or above, which is the threshold that trial enrolled. The real remaining question is whether to initiate below 20, which none of the major trials were designed to test.
Glucose Control Fades, but Kidney Protection Remains
One reason the eGFR threshold was originally set higher was that the drugs’ ability to lower blood sugar depends on how much glucose is being filtered, which drops as kidney function worsens. In patients with eGFR between 60 and 90, empagliflozin lowered hemoglobin A1c by about 0.7 percentage points compared to placebo. At lower eGFR levels, that glucose-lowering effect diminishes substantially.13Elsevier / American Journal of Kidney Diseases. SGLT2 Inhibition for the Prevention and Treatment of Diabetic Kidney Disease: A Review Early on, regulators understandably saw a drug that stops working for its primary purpose (lowering glucose) as a drug that should be stopped. But the kidney and heart benefits turned out not to depend on glucose lowering at all. That disconnect is the single most important reason the eGFR threshold has moved.
This is also why SGLT2 inhibitors are now used in people without diabetes. The drug’s hemodynamic, anti-inflammatory, and antifibrotic effects protect the kidneys through pathways that have nothing to do with blood sugar. A systematic review and meta-analysis found that SGLT2 inhibitors reduced kidney disease progression by 27% to 57% and heart failure outcomes by 13% to 32% across different eGFR categories, with low variation between groups.14PubMed. Impact of baseline kidney function on the effects of sodium-glucose co-transporter-2 inhibitors on kidney and heart failure outcomes: A systematic review and meta-analysis of randomized controlled trials
Continuing Below the Initiation Threshold
A separate question from “when can you start?” is “when should you stop?” The two answers are different. Even if a drug can only be initiated at eGFR 20, current guidance supports continuing it when eGFR falls below that number over time, which is expected to happen in many patients with progressive CKD.
A CREDENCE subgroup analysis looked at patients whose eGFR dropped below 20 while on canagliflozin. Continuing the drug was associated with persistent kidney and cardiovascular benefits and no additional safety concerns compared to placebo.15Journal of Cardiac Failure. Sodium-glucose Cotransporter 2 Inhibition in Patients With Type 2 Diabetes and Chronic Kidney Disease Experiencing a Deterioration in Estimated Glomerular Filtration Rate to <20 mL/min/1.73 m2 While rates of adverse events like hyperkalemia and kidney-related events were higher in these sicker patients overall, canagliflozin did not increase those risks compared to placebo.16European Heart Journal. Canagliflozin in patients with type 2 Diabetes and CKD experiencing deterioration in eGFR to <20 ml/min/1.73m2 in the CREDENCE Trial Both analyses concluded that the data support continuing SGLT2 inhibitors until dialysis or transplantation.
This distinction between initiation and continuation thresholds is sometimes missed by prescribers. A patient who was started on an SGLT2 inhibitor at eGFR 25 and whose function declines to 18 should, in most cases, stay on the drug. Stopping it reflexively because eGFR crossed a number on a chart could mean losing the very protection that’s slowing the decline.
The Heart Failure Connection
SGLT2 inhibitors were approved for heart failure in their own right, and the kidney-heart relationship runs both ways. In the DAPA-HF trial, which studied dapagliflozin in heart failure with reduced ejection fraction, the drug’s benefit on the primary endpoint was similar whether or not patients had chronic kidney disease at baseline.17PubMed Central. Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF The consistency of benefit across different types of heart failure, kidney disease, and diabetes status is unusual for a drug class and has been confirmed across multiple large trials.18Nature Reviews Nephrology. Kidney and heart failure outcomes associated with SGLT2 inhibitor use
For patients with both heart failure and reduced kidney function, this means there are two independent reasons to be on the drug, and neither reason disappears at a lower eGFR. This is relevant to the cut-off discussion because a patient who might not meet the kidney-disease threshold for initiation could meet the heart failure threshold, or vice versa, and the organ protection overlaps.
The Acute Kidney Injury Question
An early and persistent worry was that a drug class causing an eGFR dip and increased urination might predispose people to acute kidney injury, especially in patients who are already dehydrated or on diuretics. The evidence has gone the other direction. Meta-analyses of large randomized trials, along with real-world cohort studies, have found that SGLT2 inhibitor use actually reduces the risk of AKI, despite causing more volume-related side effects like dizziness on standing. One analysis found a hazard ratio of 0.64 for AKI in SGLT2 inhibitor users, though this didn’t quite reach statistical significance.19PubMed Central. SGLT2 Inhibitors and the eGFR Cut-Off: What It Means The overall body of evidence from trials and propensity-matched real-world data shows that these drugs do not predispose to clinically significant AKI and likely protect against it.
That said, sensible precautions around hydration and sick-day management apply. If you’re ill with vomiting or diarrhea, or undergoing a procedure where you’ll be fasting and potentially dehydrated, temporarily holding the drug is standard practice. This is practical volume management, not a signal that the drug is inherently risky for the kidneys.
Evidence in Very Advanced Kidney Disease
A recent systematic review and meta-analysis pooled ten randomized controlled trials including about 4,800 patients with eGFR below 30. SGLT2 inhibitor use was associated with a 21% lower incidence of the primary kidney composite outcome in this advanced group. The cardiovascular composite trended lower as well, though with wider confidence intervals given the smaller numbers. There was no interaction between advanced CKD status and treatment effect for any primary or secondary outcome, and adverse event rates were similar between the drug and placebo arms.20PubMed Central. Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with and without Advanced CKD Systematic Review and Meta-Analysis
A smaller observational study of 66 patients with stage 4-5 CKD (mean eGFR around 21) treated with dapagliflozin found that eGFR remained largely stable over 12 months, and protein in the urine decreased. Only 4 patients discontinued due to abdominal pain, and no severe adverse events were reported.21Nephrology Dialysis Transplantation. Breaking barriers in nephroprotection for advanced chronic kidney disease: SGLT2 inhibitors in the treatment of CKD Stage 4–5 The evidence base at very low eGFR levels is still thinner than at moderate CKD, but everything so far points in the same direction.
Non-Diabetic Kidney Diseases
The eGFR cut-off conversation originally centered on type 2 diabetes, because that’s where the drugs were first approved. But the benefits extend to non-diabetic kidney diseases as well. IgA nephropathy, one of the most common forms of glomerulonephritis worldwide, has been studied specifically. One analysis found that SGLT2 inhibitors reduced protein in the urine by about 23% at three months and 27% at six months, with the antiproteinuric effect holding across age groups, baseline proteinuria levels, eGFR levels, and whether or not immunosuppressive therapy was being used.22Frontiers in Medicine. Effect of SGLT2 inhibitors on the proteinuria reduction in patients with IgA nephropathy EMPA-KIDNEY’s broad enrollment criteria, which included multiple causes of CKD, reinforced the idea that the mechanism of benefit is not disease-specific.10PubMed Central. SGLT2 Inhibitors and the eGFR Cut-Off: What It Means
This matters for the eGFR cut-off because it means the threshold applies to a much wider population than was originally imagined. Someone with IgA nephropathy and an eGFR of 25, who was previously not a candidate for these drugs, now has strong reason to be on one.
Combining SGLT2 Inhibitors with Finerenone
The newest frontier in kidney protection involves layering SGLT2 inhibitors with finerenone, a non-steroidal mineralocorticoid receptor antagonist. The two drug classes attack kidney disease through complementary pathways: SGLT2 inhibitors work primarily through hemodynamic effects and tubuloglomerular feedback, while finerenone targets inflammation and fibrosis driven by mineralocorticoid receptor overactivation.
Early data are encouraging. Over two years of follow-up, patients on triple combination therapy (SGLT2 inhibitor plus finerenone plus standard renin-angiotensin blockade) had a 47% greater reduction in proteinuria compared to dual therapy without finerenone. The rate of annual eGFR decline was slowed by about 1.3 to 1.5 points per year compared to SGLT2 inhibitor therapy alone.23PubMed. Adding Finerenone to SGLT2 Inhibitors and Long-Term Kidney Outcomes in Diabetic Kidney Disease Potassium levels rose modestly at first but stabilized, with no clinically significant hyperkalemia events in one cohort study.24PubMed Central. Efficacy and safety of add-on treatment with finerenone in patients with diabetic kidney disease already treated with SGLT-2 inhibitors Potassium monitoring is still important with this combination, especially early on, but the safety profile so far looks manageable.
The Cost-Effectiveness Angle
SGLT2 inhibitors are not cheap drugs, and at lower eGFR levels where the glucose-lowering benefit has faded, the question of whether they’re worth the ongoing cost is reasonable. The economic modeling, though, has been favorable. A Dutch analysis of empagliflozin in CKD found that while treatment and monitoring costs were higher, the drug delayed progression to end-stage kidney disease by roughly three additional years compared to standard care alone. The savings from avoided dialysis and kidney replacement therapy resulted in net cost savings of over €34,000 per patient over a lifetime horizon.25PLOS ONE. Cost effectiveness of empagliflozin in adult patients with chronic kidney disease in the Netherlands
A broader systematic review of cost-effectiveness studies for nephroprotective therapies in CKD, including SGLT2 inhibitors, concluded that these treatments are generally cost-effective and in some healthcare settings actually cost-saving. The economic case gets stronger the earlier treatment starts, since delaying kidney disease progression avoids the enormous expenses associated with dialysis.26PubMed Central. Chronic Kidney Disease (CKD): Systematic Review of the Cost Effectiveness of SGLT2 Inhibitors and Other Novel Nephroprotective Drugs This is another reason the lowered eGFR threshold matters practically: the population of people who can now benefit from these drugs has expanded considerably, and the financial math supports treating them.